Evidence map›Paper›PMID 39686656›Full record

ReviewDiagnosis (Berlin, Germany)2025

Challenges and barriers for the adoption of personalized medicine in Europe: the case of Oncotype DX Breast Recurrence Score

Denis Horgan, Paul Hofman, Patrizio Giacomini, France Dube, Jaya Singh, Daniel Schneider, Tanya Hills, Jennifer Faikish, Marc Van Den Bulcke, Umberto Malapelle and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Diagnosis (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Denis HorganEuropean Alliance for Personalised Medicine, Brussels, Belgium.
Paul HofmanCôte d'Azur University, FHU OncoAge, IHU RespirERA, Laboratory of Clinical and Experimental Pathology, Louis Pasteur Hospital, Nice, France.
Patrizio GiacominiClinical Trial Center, Biostatistics and Bioinformatics, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
France DubeAstra Zeneca, Wilmington, DE, USA.
Jaya SinghEuropean Alliance for Personalised Medicine, Brussels, Belgium.
Daniel SchneiderN-Power Medicine, Redwood City, CA, USA.
Tanya HillsBoehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
Jennifer FaikishAmgen Inc, 20 W Manilla Ave, Pittsburgh, PA, USA.
Marc Van Den BulckeBelgian Cancer Centre, Sciensano, Brussels, Belgium.
Umberto MalapelleDepartment of Public Health, University Federico II of Naples, Naples, Italy.
Maciej GajewskiExact Sciences, Baar, Switzerland.
Vivek SubbiahSarah Cannon Research Institute, Nashville, TN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Personalized medicine, aiming to tailor treatments based on individual patient characteristics, holds immense potential in oncology. However, its widespread adoption in Europe faces numerous challenges, as illustrated by the case study of the Oncotype DX Breast Recurrence Score

Indexed as

Breast NeoplasmsNeoplasm Recurrence, LocalPrecision MedicineChemotherapy, AdjuvantEuropeFemaleGene Expression ProfilingGenetic TestingHumanscancer careclinical integrationOncotype DXpersonalized medicinereimbursement mechanisms

Identifiers

PMID39686656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.